All News

smoking.jpg

Smoking Impairs Methotrexate Efficacy

d Jack Cush, MD

The Journal of Rheumatology reports that current smoking significantly reduces the clinical efficacy of methotrexate (MTX)-based therapy, as studied in an early rheumatoid arthritis (RA) cohort.

Read Article
syringe, pill, DMARD, Treatment, therapy

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Insights

d Jack Cush, MD

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are among the most severe drug reactions, as they come with substantial mortality and morbidity.  A review of European centers dealing with SJS and TEN shows that despite best treatment practices, the 6-week mortality rate was 21%.

Read Article
CV,risk,MI,heart,cardiac

Heart Failure in RA: Inflammation Matters

d MedPage Today

Patients with rheumatoid arthritis (RA) who had high levels of inflammation at baseline were at increased risk for later heart failure, a large cohort study found.

Read Article
COVID Test Antibody

Is It OK to Continue TNF Inhibitors with COVID-19 Infection?

d Jack Cush, MD

Registry level data of patients with immune-mediated inflammatory diseases (IMIDs) diagnosed with COVID-19 should continue their TNF inhibitor (TNFi) therapy as such patients were less likely to experience adverse COVID-19 outcomes (compared to other immunomodulatory treatments).

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

NOBILITY: a Trial of Obinutuzumab in Proliferative Lupus Nephritis

d Jack Cush, MD

B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.

Read Article
September’s most popular read: 11 Drugs That Cause Arthritis https://t.co/GsV0Qj9ENr https://t.co/DNI9bqgKym

Links:

Dr. John Cush RheumNow ( View Tweet)
In PsA trials, over time the (ACR20) placebo response has increased (15% every 5 yrs)but was not associated with the active treatment effect size. 42 RCTs, the pooled placebo response was 20.3%; pooled treatment effect vs placebo was 27% https://t.co/b9LRpvcTir

Links:

Dr. John Cush RheumNow ( View Tweet)

Adalimumab biosimilar AVT02 equivalent to Originator Humira in Moderate to Severe Chronic Plaque Psoriasis patients with a PASI score at Week 16 of 91.6% for AVT02vs 89.6% for Humira https://t.co/dO4g4aOuON

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Drug Safety Risk Communication- The 800 lb Gorilla Approach | #RheumNow https://t.co/6iSJjvlFF8 https://t.co/6egrpCVuaG

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Steroid Poker https://t.co/kJOmCyIpzM https://t.co/A6EkxcIcHG

Links:

Dr. John Cush RheumNow ( View Tweet)
In a real world study of lupus patients, aspirin use lowered risk of preeclampsia, as did hydroxychloroquine. Risk Factors for preeclampsia were high Dz activity 1st trimester (OR 4.55), BMI >30 (6.14), antiphospholipid synd (8.02), hx preeclampsia (9.8)https://t.co/giBamMAPRM

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA reports the COVID-19 combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% By May 2021, there were 2.1 SARS-CoV-2 infections per reported COVID-19 case. https://t.co/bUZ5AqYnxM

Links:

Dr. John Cush RheumNow ( View Tweet)

Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d. (Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: Dr. Robert Chao ( @doctorRBC ) reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented at the virtual EULAR 2021 meeting. https://t.co/7FmZ4BzHwp

Links:

Dr. John Cush RheumNow ( View Tweet)

B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies. https://t.co/pMXWmuJw5Y https://t.co/1raYa1vLtK

Links:

Dr. John Cush RheumNow ( View Tweet)
TICOSPA - Does Treat to Target Work in Spondyloarthritis? https://t.co/ibavOjmBJd https://t.co/DseCTMRX7J

Links:

Dr. John Cush RheumNow ( View Tweet)
PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 14.9% UST vs 19.2% TNFk and Minimal Dz Activity was 26.4% UST vs 30.8% TNFi at 6 months - both were equipotent in PsA https://t.co/RLadZa6YTI https://t.co/I7eKxD3XyI

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast titled Quackademia available for download wherever you get your podcasts! https://t.co/Y6Pqko1tYm https://t.co/6RU1nuj7QU

Links:

Dr. John Cush RheumNow ( View Tweet)
Congratulations to friend and mentor, Dr. Stan Cohen for receiving this years ACR Gold Medal award - the highest award that the ACR can bestow. Stan was a past ACR President & has been a leading educator and researcher in rheumatology https://t.co/EJQ5tc3dhc

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves Cyltezo, the 1st INTERCHANGEABLE Biosimilar to Humira - interchangeable means this biosimilar may be substituted for the Humira without the prescriber notice (by pharmacy)in same way generics are substituted for brand name drugs https://t.co/xvinL7UKNU

Links:

Dr. John Cush RheumNow ( View Tweet)

×